PDGFRA and gastrointestinal stromal tumor: In addition, because PDGFRA-mutant GIST accounts for up to 10% of GISTs that exhibits primary resistance to imatinib and sunitinib therapy [165], other agents that selectively target PDGFRa D842V mutant advanced GISTs are of immense clinical value.